[go: up one dir, main page]

UA99659C2 - Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування - Google Patents

Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування

Info

Publication number
UA99659C2
UA99659C2 UAA201015812A UAA201015812A UA99659C2 UA 99659 C2 UA99659 C2 UA 99659C2 UA A201015812 A UAA201015812 A UA A201015812A UA A201015812 A UAA201015812 A UA A201015812A UA 99659 C2 UA99659 C2 UA 99659C2
Authority
UA
Ukraine
Prior art keywords
outer membrane
methods
making
membrane vesicle
native outer
Prior art date
Application number
UAA201015812A
Other languages
English (en)
Russian (ru)
Inventor
Уенделл Девід Золлінгер
Міхаіл Донєц
Дебора Шміль
Боріс Іонін
Райан МАРКЕС
Елізабет Еллен Моран
Original Assignee
Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі filed Critical Дзе Ю.Ес.Ей., Ес Репрезентед Бай Дзе Секретарі Оф Дзе Армі, Он Бехаф Оф Уолтер Рід Армі
Publication of UA99659C2 publication Critical patent/UA99659C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Даний спосіб належить до композиції вакцин, що містить нативні везикули зовнішньої мембрани менінгококів (NOMV) щонайменше з двох генетично модифікованих штамів Neisseria, що забезпечує захисний імунітет проти менінгококової інфекції, більш переважно, інфекції, що викликається менінгококами підтипу В. Заявлений спосіб також належить до способів імунізації тварини або людини проти менінгококової інфекції, що включають в себе введення вакцинної композиції за даним винаходом.
UAA201015812A 2008-05-30 2009-06-01 Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування UA99659C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5746208P 2008-05-30 2008-05-30
PCT/US2009/045818 WO2009158142A1 (en) 2008-05-30 2009-06-01 Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof

Publications (1)

Publication Number Publication Date
UA99659C2 true UA99659C2 (uk) 2012-09-10

Family

ID=41444870

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201015812A UA99659C2 (uk) 2008-05-30 2009-06-01 Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування

Country Status (19)

Country Link
US (2) US9387239B2 (uk)
EP (1) EP2296699A4 (uk)
JP (2) JP5723768B2 (uk)
KR (1) KR20110053314A (uk)
CN (1) CN102105166A (uk)
AU (1) AU2009262893B2 (uk)
BR (1) BRPI0913268A2 (uk)
CA (1) CA2726465A1 (uk)
CO (1) CO6341569A2 (uk)
CR (1) CR11812A (uk)
DO (1) DOP2010000364A (uk)
EC (1) ECSP10010723A (uk)
IL (1) IL209660A0 (uk)
MX (1) MX2010012999A (uk)
NZ (1) NZ589812A (uk)
RU (1) RU2477145C2 (uk)
UA (1) UA99659C2 (uk)
WO (1) WO2009158142A1 (uk)
ZA (1) ZA201008548B (uk)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2838395C (en) 1999-05-19 2016-07-19 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP2544714A1 (en) * 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
DK3246044T4 (da) 2010-08-23 2024-05-21 Wyeth Llc Stabile formuleringer af Neisseria-meningitidis-RLP2086-antigener
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012032498A2 (en) * 2010-09-10 2012-03-15 Novartis Ag Developments in meningococcal outer membrane vesicles
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
MX2014002375A (es) 2011-08-31 2014-09-15 Children S Hospital & Res Ct Oakland Secuencias diseñadas para facilitar la expresion de antigenos en neisseria y metodos de uso.
WO2013113917A1 (en) 2012-02-02 2013-08-08 Novartis Ag Promoters for increased protein expression in meningococcus
ES2750366T3 (es) 2012-03-08 2020-03-25 Glaxosmithkline Biologicals Sa Ensayo de potencia in vitro para vacunas meningocócicas basadas en proteína
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101452830B1 (ko) * 2012-04-06 2014-10-21 아이진 주식회사 두 가지 항암물질을 동시에 제공하는 대장균 균주
MX363529B (es) 2012-09-18 2019-03-27 Novartis Ag Vesículas de membrana externa.
JP6446377B2 (ja) 2013-03-08 2018-12-26 ファイザー・インク 免疫原性融合ポリペプチド
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
BR112018015237A2 (pt) * 2016-01-28 2018-12-26 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport lps de neisseria hexa-acilado modificado
EP3263695A1 (en) * 2016-06-29 2018-01-03 GlaxoSmithKline Biologicals SA Immunogenic compositions
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
MX2019006105A (es) * 2016-11-25 2019-08-21 Glaxosmithkline Biologicals Sa Conjugados de vmen-antigeno y uso de los mismos.
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN107961369B (zh) * 2017-03-22 2020-08-11 武汉博沃生物科技有限公司 多价脑膜炎球菌缀合疫苗及其制备方法
US12502427B2 (en) 2019-03-21 2025-12-23 Lonza Sales Ag Extracellular vesicles for vaccine delivery
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN113151354B (zh) * 2021-03-22 2022-03-08 中国农业科学院兰州兽医研究所 一种用于条件性敲除目的基因的载体及条件性敲除目的基因的方法
CN119020251A (zh) * 2024-08-26 2024-11-26 南昌大学 一株脂多糖修饰b群脑膜炎球菌与其外膜囊泡制备及应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ES2070312T5 (es) 1988-12-19 2003-05-16 American Cyanamid Co Vacuna de proteina de membrana exterior meningococica de clase 1.
US7118757B1 (en) * 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
DE4023721A1 (de) 1990-07-26 1992-01-30 Boehringer Mannheim Gmbh Verfahren zur herstellung von vakzinen und ihre verwendung
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
NL9201716A (nl) * 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
US7112332B1 (en) * 1992-10-08 2006-09-26 The United States Of America As Represented By The Secretary Of The Army Oral or intranasal vaccines using hydrophobic complexes having proteosomes and lipopolysaccharides
ES2145072T3 (es) * 1993-05-13 2000-07-01 American Cyanamid Co Preparacion y usos de proteinas de membranas externas carentes de los de cocos gramnegativos.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1997010844A1 (en) * 1995-09-18 1997-03-27 United States Army Medical Research Materiel Command (Usamrmc) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20030215469A1 (en) * 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
DE60038099T2 (de) 1999-02-22 2009-02-19 Health Protection Agency, Salisbury Neisseria impfstoffzusammensetzungen und methoden
GB9918319D0 (en) * 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
NZ520466A (en) * 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
ES2375704T5 (es) * 2000-06-29 2016-03-03 Smithkline Beecham Biologicals S.A. Composición de vacuna multivalente
GB0103170D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
GB0103169D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1372528B1 (en) * 2001-04-05 2013-01-02 Novartis Vaccines and Diagnostics, Inc. Mucosal boosting following parenteral priming
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
EP1374892A1 (en) * 2002-06-28 2004-01-02 Braun, Jan Matthias, Dr. Medicament for the treatment of diseases due to infection by Neisseria Meningitidis
MY149591A (en) 2002-08-02 2013-09-13 Glaxosmithkline Biolog Sa Vaccines comprising l2 and/or l3 los from neisseria
CU23377A1 (es) 2003-11-04 2009-05-28 Ct De Ingenieria Genetica Y Biotecnologia Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
JP5173194B2 (ja) * 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
JP5174457B2 (ja) * 2004-05-11 2013-04-03 デ スタート デール ネーダーランデン， フェルテヘンウォールディヒィト ドール デ ミニステール ファン フォルクスヘーゾンドハイド， フェルザイン アン スポルト アジュバントとしての髄膜炎菌ｌｇｔＢＬＯＳ
US7537766B2 (en) * 2004-08-30 2009-05-26 Wyeth Neisseria meningitidis inner core lipo-oligosaccharide epitopes, multivalent conjugates thereof and immunogenic compositions thereof
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
US9034345B2 (en) 2005-01-27 2015-05-19 Children's Hospital & Research Center Oakland GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
EP2032161B1 (en) 2006-06-12 2012-07-11 GlaxoSmithKline Biologicals S.A. L3v los vaccines

Also Published As

Publication number Publication date
NZ589812A (en) 2012-08-31
BRPI0913268A2 (pt) 2016-03-15
AU2009262893A1 (en) 2009-12-30
CN102105166A (zh) 2011-06-22
CR11812A (es) 2011-07-06
US20110182942A1 (en) 2011-07-28
AU2009262893B2 (en) 2015-05-21
EP2296699A1 (en) 2011-03-23
RU2477145C2 (ru) 2013-03-10
ECSP10010723A (es) 2011-05-31
JP5723768B2 (ja) 2015-05-27
US9387239B2 (en) 2016-07-12
CA2726465A1 (en) 2009-12-30
JP2015061870A (ja) 2015-04-02
AU2009262893A9 (en) 2015-05-21
EP2296699A4 (en) 2013-11-13
KR20110053314A (ko) 2011-05-20
IL209660A0 (en) 2011-02-28
CO6341569A2 (es) 2011-11-21
MX2010012999A (es) 2012-03-07
WO2009158142A1 (en) 2009-12-30
JP2011521976A (ja) 2011-07-28
ZA201008548B (en) 2012-06-27
RU2010153658A (ru) 2012-08-10
US20170100471A1 (en) 2017-04-13
DOP2010000364A (es) 2011-07-15

Similar Documents

Publication Publication Date Title
MX2010012999A (es) Vacuna de vesícula de membrana externa nativa multivalente del meningococo, método para su fabricación y uso.
AR118199A2 (es) Composiciones inmunogénicas de variantes no lipidadas no piruviladas de antígenos orf2086 de neisseria meningitidis, polipéptidos, secuencias de nucleótidos y plásmidos
IN2014DN08830A (uk)
MX375202B (es) Composiciones adyuvantes novedosas.
WO2010037395A3 (en) Mhc multimers in cancer vaccines and immune monitoring
AU2009326524A8 (en) Use of Flt3 ligand for strengthening immune responses in RNA immunization
NO20083722L (no) Immunogen sammensetning
IN2012DN02736A (uk)
MX2009008928A (es) Composiciones que comprenden conjugados de polisacaridos y su uso como vacunas.
PE20142115A1 (es) Composiciones de neisseria meningitidis y metodos de las mismas
WO2009039854A3 (en) Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
BRPI0607374A2 (pt) vacinas de vesìculas baseadas em gna1870 para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
DK2459216T3 (da) Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
CA2763359C (en) New human rotavirus strains and vaccines
MX357538B (es) Vacunas para meningococo de serogrupo x.
DE60336588D1 (de) Verbesserte anthraximpfstoffe und abgabeverfahren
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
WO2009105192A3 (en) Use of saccharides cross-reactive with bacillus anthracis spore glycoprotein as a vaccine against anthrax
WO2010080188A3 (en) Epitope targeted anthrax vaccine
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
MY158116A (en) Combination vaccine against streptococcus
ATE424844T1 (de) Kombinationsvakzine für geflügel
DE602005021873D1 (de) Neues impfstoffadjuvans und dessen herstellung und verwendung
WO2008100142A3 (en) Vaccine formulation
BR112012033751A2 (pt) composição de vacina, célula, adjuvante, método de vacinar um paciente contra e. canis e processos para produzir a composição de vacina e o antígeno de e. canis